Full Breakdown
FDA Grants Accelerated Approval to Vera Therapeutics’ Trutakna for IgA Nephropathy
7/10/2026, 1:54:48 PM
FDA Approval and Indication
The U.S. Food and Drug Administration granted accelerated approval to Trutakna (atacicept), a dual BAFF/APRIL inhibitor, for adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of disease progression. The decision is based on interim results from the Phase 3 ORIGIN 3 trial, which showed a 46% reduction in proteinuria from baseline and a 42% greater reduction versus placebo after 36 weeks. Trutakna will be marketed by Brisbane, California-based Vera Therapeutics at a list price of $425,000 per year.
Background & Context
IgAN is a rare autoimmune kidney disorder affecting roughly 160,000 people in the United States. Until 2021, treatment relied on off-label use of blood-pressure agents and corticosteroids such as Calliditas Therapeutics’ Tarpeyo (budesonide). The first disease-specific therapy, Otsuka Pharmaceutical’s Voyxact (sibeprenlimab), received accelerated approval in November 2023 as a monoclonal antibody that blocks APRIL. Trutakna is the first FDA-cleared drug that simultaneously blocks both BAFF and APRIL, a mechanism intended to more comprehensively suppress the auto-antibody production driving IgAN.
Data & Statistics
- Proteinuria reduction: 46% from baseline; 42% greater than placebo at 36 weeks (ORIGIN 3).
- Adverse events: Most common were infections and local injection-site reactions.
- Pricing: $425,000 annual list price for Trutakna versus $390,000 for Voyxact.
- Market landscape: Six IgAN therapies are currently approved in the U.S., including Tarpeyo, Voyxact, Travere Therapeutics’ Filspari (sparsentan), Novartis’ Fabhalta (iptacopan) and Vanrafia (atrasentan), and AstraZeneca’s Ultomiris (ravulizumab). Additional late-stage candidates include Vertex’s povetacicept, Ionis/Roche’s IONIS-FB-LRx/RG6299, and Biogen’s felzartamab.
Official Statements & Responses
Vera Therapeutics’ chief executive Marshall Fordyce described the approval as “an important milestone” for patients and emphasized the potential to “meaningfully transform the treatment landscape.” Otsuka has indicated that data from its two-year VISIONARY study are ready, and the company plans a rolling submission for full approval later this year. The FDA noted that accelerated approval will require confirmatory data demonstrating a sustained benefit on estimated glomerular filtration rate (eGFR), which Vera expects to report later this quarter.
Criticism & Opposition
Analyst Myles Minter of William Blair highlighted that Trutakna’s higher incidence of injection-site reactions could affect patient preference, especially given Voyxact’s earlier market entry. He also warned that Vertex’s povetacicept, another dual BAFF/APRIL inhibitor currently under FDA review with a decision target of 30 Nov 2026, may intensify pricing pressure and fragment market share.
Verbatim Quotes
- “has the potential to meaningfully transform the treatment landscape.” — Marshall Fordyce, CEO, Vera Therapeutics
- “Ultimately, we still believe the profiles of Voyxact and Trutakna leave room for better follow-on IgAN therapies with improved efficacy and patient convenience, including Vertex’s dual BAFF/APRIL inhibitor povetacicept, and the half-life extended APRIL antibodies from Jade Bio (JADE101) and Climb Bio (CLYM116),” — Myles Minter, Analyst, William Blair
Conflicting Reports & Gaps
No direct head-to-head comparative trials between Trutakna and Voyxact have been disclosed, leaving uncertainty about relative efficacy and safety. Long-term outcomes on eGFR decline remain pending until the confirmatory Phase 3 data are released.
What’s Next
Vera will submit additional clinical data from the ongoing confirmatory trial later this quarter to satisfy the FDA’s requirement for verification of safety and clinical benefit. Vertex expects a regulatory decision on povetacicept by 30 Nov 2026, which could reshape competitive dynamics in the IgAN market.
